RANDOX

Randox is dedicated to improving healthcare using innovative diagnostic technologies, for a range of health conditions including heart disease, diabetes, Alzheimer’s disease, cancer and stroke. Whilst the science is complex, the applications are not.

The Randox ethos of improving healthcare, which drove their Managing Director Dr Peter FitzGerald to start the company in the 1980s, continues today. Up to 25% of their turnover is reinvested in research and development to enable scientists to work on the development of pioneering tests for a range of common illnesses such as cancer, cardiovascular disease and Alzheimer’s disease.

RANDOX also spent more than £220 million developing the patented Randox Biochip. This state-of-the-art biochip technology has revolutionized the diagnostics industry because it allows multiple tests to be carried out from a single, undivided patient sample on a single testing platform.